Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03487952
Other study ID # NCLUNG
Secondary ID
Status Not yet recruiting
Phase
First received March 21, 2018
Last updated March 27, 2018
Start date April 2018
Est. completion date December 2021

Study information

Verified date March 2018
Source Peking University People's Hospital
Contact Jun J Wang, MM
Phone +8601088326650
Email xiongwai@263.net
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Lung cancer is one of the leading cause of cancer related death in China. Lung cancer screening with low-dose computed tomography was considered as a better approach than radiography. However, the role of Lung cancer screening with Low-dose CT (LDCT) among Chinese people remains unclear. With rapid development of artificial intelligence (AI),the application of AI in detection and diagnosis of diseases has become research focus. Moreover, patients' psychological status also plays an important role in diagnosis and treatment.

This study focuses on detection and natural history management of lung nodule and lung cancer with AI assisted chest CT among people living in North China, and aims to investigate epidemiological results, patients' medical records and social psychological status.


Description:

Lu'an Municipal Hospital and North China Petroleum Bureau General Hospital initialed the lung cancer screening by LDCT a few years ago. People living in North China who are administrated by these hospitals routinely took a chest CT every year. This study is to the best of our knowledge the first one designed to combine lung nodule and lung cancer screening with the application of artificial intelligence in China.

Methods: Firstly, the study acquires epidemiological, medical information and psychological status of people recruited, and investigates the data acquired from past several years of CT scans using AI to develop a model for lung nodule detection. Secondly, evaluating the performance of models and apply it to analyse the CT scans from the North China population recruited. Thirdly, improving the model and adding function for lung nodule prediction of natural history and probability of malignancy.

Aims: To depict the epidemiological results about the incidence of lung nodules and lung cancer in North China population; To evaluate association between people 's epidemiological, medical and psychological profiles and incidence, diagnosis and treatment of lung nodule; To develop an artificial intelligence assisted lung nodule diagnosis and management software to assist strategies of CT screening.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 5000
Est. completion date December 2021
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria:

- Aged 40 years or older

- Routinely conducting chest CT scan at a low-dose setting (120kVp, 40-80mA, slice thickness of 1.25 mm or less) yearly in Lu'an Municipal Hospital and North China Petroleum Bureau General Hospital in at least the past 4 years up to December 2017, willing to continue routine yearly LDCT scan.

- Chest CT data are available for DICOM format.

- Signed Informed Consent Form.

Exclusion Criteria:

- Pregnant woman and the disabled

- Past thoracic surgery history, except for diagnostic thoracoscopy

- Poor physical status without sufficient respiratory reserve to undergo lobectomy if necessary

- Shortened life expectancy less than 10 years

- Malignant tumor history within the past 5 years, except for the following conditions: cured skin basal cell carcinoma, superficial bladder carcinoma. and uterine cervix cancer in situ.

- Past history of interstitial lung disease, pulmonary bulla and lung tuberculosis.

- Other circumstances which is deemed inappropriate for enrollment by the researchers.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Questionnaire Administration
Subjects will be asked to complete an additional detailed questionnaire regarding personal information, smoking history, medical history, their diet and lifestyle habits, family history of malignant neoplasm, any past or current environmental exposures and psychological status.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Peking University People's Hospital Lu'an Municipal Hospital, North China Petroleum Bureau General Hospital

References & Publications (7)

Baldwin DR, Callister ME; Guideline Development Group. The British Thoracic Society guidelines on the investigation and management of pulmonary nodules. Thorax. 2015 Aug;70(8):794-8. doi: 10.1136/thoraxjnl-2015-207221. Epub 2015 Jul 1. Review. — View Citation

Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e78S-e92S. doi: 10.1378/chest.12-2350. Review. — View Citation

Field JK, Oudkerk M, Pedersen JH, Duffy SW. Prospects for population screening and diagnosis of lung cancer. Lancet. 2013 Aug 24;382(9893):732-41. doi: 10.1016/S0140-6736(13)61614-1. Review. — View Citation

Harris RP, Sheridan SL, Lewis CL, Barclay C, Vu MB, Kistler CE, Golin CE, DeFrank JT, Brewer NT. The harms of screening: a proposed taxonomy and application to lung cancer screening. JAMA Intern Med. 2014 Feb 1;174(2):281-5. doi: 10.1001/jamainternmed.2013.12745. Review. Erratum in: JAMA Intern Med. 2014 Mar;174(3):484. — View Citation

National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29. — View Citation

Silva M, Pastorino U, Sverzellati N. Lung cancer screening with low-dose CT in Europe: strength and weakness of diverse independent screening trials. Clin Radiol. 2017 May;72(5):389-400. doi: 10.1016/j.crad.2016.12.021. Epub 2017 Feb 4. Review. — View Citation

Wiener RS, Gould MK, Woloshin S, Schwartz LM, Clark JA. What do you mean, a spot?: A qualitative analysis of patients' reactions to discussions with their physicians about pulmonary nodules. Chest. 2013 Mar;143(3):672-677. doi: 10.1378/chest.12-1095. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Detection rate of lung nodule Study participants undergo baseline LDCT. Images are reviewed via AI software independently to identify lung nodules with diameters greater than 4mm. The software is developed by our computer technology collaborator. A radiologist then reviews the images, reports lung nodules with diameters greater than 4mm and any other abnormalities. The radiologist's findings will be conveyed to the study participants or their primary care physicians within 3 weeks. The process was conducted via double-blind method and detection rates of AI and radiologist will be recorded respectively. Unit of measurement: Percentage (number of participants with detected lung nodules over the total number of participants). 3 months
Primary Profile of detected lung nodule All lung nodules detected will be classified as 4 classes by the density and composition of nodule: 1. pure ground-glass nodule (pGGN); 2. part-solid nodule; 3. solid nodule; 4. uncertain nodule. The number and proportion of each class and the diameter and location of each nodule will be recorded. Unit of measurement: Percentage (number of nodules in each class over the total number of nodules); Numerical value (average value±standard deviation of nodules in each class); Percentage (number of nodules in each lobe over the total number of nodules). 3 months
Secondary Sensitivity in the detection of clinically actionable lung nodules AI assisted CT compared with conventional CT read via radiologist. Unit of measurement: Percentage (detected actionable lung nodules over the total number of actionable nodules). 3 months
Secondary Growth of lung nodule Study participants undergo baseline LDCT and subsequent yearly LDCT. Making use of these consecutive CT images, volume doubling time (VDT) for each lung nodule can be calculated via software and can be used to evaluate growth of nodule. cUnit of measurement: Numerical value (volume doubling time, VDT). 3 years
Secondary Anxiety and depression level Hospital Anxiety and Depression Scale (HADS) is included in our questionnaire and score of this scale will be recorded. Unit of measurement: Numerical value (score of scale). 3 months
Secondary Life quality and health status The MOS item short from health survey (SF-36) is included in our questionnaire and score of this scale will be recorded. Unit of measurement: Numerical value (score of scale). 3 months
Secondary Lung cancer detection rate Percentage (the number of detected lung nodules which was finally diagnosed as primary lung cancer over the total number of detected lung nodules) 3 months
See also
  Status Clinical Trial Phase
Terminated NCT05066776 - Liquid Biopsy With PET/CT Versus PET/CT Alone in Diagnosis of Small Lung Nodules
Completed NCT01958931 - Evaluate the Utility of the ProLung Test as Adjunctive to CT Scan in the Diagnosis of Lung Cancer N/A
Recruiting NCT03528733 - Feasibility of Multi-Energy Digital Radiography Detector for Lung Lesions Detection N/A
Recruiting NCT02693496 - Mobile Lung Nodule Observatory for Worldwide, Evidenced-based Research
Completed NCT01566682 - A Multi-Center Trial of the ProLung Test™
Terminated NCT02983903 - Cryobiopsy Versus Forceps Biopsy for Pulmonary Lesions N/A
Terminated NCT02050724 - ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT Phase 2
Not yet recruiting NCT04615156 - 18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography Phase 3
Recruiting NCT02726633 - Evaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer N/A
Active, not recruiting NCT02623712 - The Watch the Spot Trial N/A
Recruiting NCT03568799 - 4-[18F]Fluoroglutamine PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules N/A
Not yet recruiting NCT02817048 - Tubeless VATS for Peripheral Lung Nodule N/A
Recruiting NCT01149187 - Usefulness of Interferon-gamma Release Assay in Diagnosing Pulmonary Nodules N/A
Completed NCT00925210 - Bronchoscopic Approach to the Peripheral Lung Nodule - An Alternative Approach Phase 2
Completed NCT02448225 - 18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules Phase 2
Active, not recruiting NCT05171491 - LungLB in Subjects Presenting With Indeterminate Pulmonary Nodules
Terminated NCT04140474 - Evaluation of the Archimedes ™ System for Transparenchymatous Access to Pulmonary Nodules. N/A
Withdrawn NCT05804435 - iNod™ Ultrasound-Guided Needle Biopsy System Study N/A
Not yet recruiting NCT02653859 - Evaluate the Auxiliary Diagnostic Value of Circulating Tumor Cells in Benign and Malignant Lung Nodules N/A
Completed NCT02832284 - iNod System Human Feasibility Assessment N/A